LT1771206T - Lipidai, lipidų kompleksai ir jų panaudojimas - Google Patents

Lipidai, lipidų kompleksai ir jų panaudojimas

Info

Publication number
LT1771206T
LT1771206T LTEP05742844.3T LT05742844T LT1771206T LT 1771206 T LT1771206 T LT 1771206T LT 05742844 T LT05742844 T LT 05742844T LT 1771206 T LT1771206 T LT 1771206T
Authority
LT
Lithuania
Prior art keywords
lipids
lipid complexes
lipid
complexes
Prior art date
Application number
LTEP05742844.3T
Other languages
English (en)
Inventor
Oliver Keil
Jörg Kaufmann
Original Assignee
Silence Therapeutics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Silence Therapeutics Gmbh filed Critical Silence Therapeutics Gmbh
Publication of LT1771206T publication Critical patent/LT1771206T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/44—Preparation of compounds containing amino groups bound to a carbon skeleton by reduction of carboxylic acids or esters thereof in presence of ammonia or amines, or by reduction of nitriles, carboxylic acid amides, imines or imino-ethers
    • C07C209/50—Preparation of compounds containing amino groups bound to a carbon skeleton by reduction of carboxylic acids or esters thereof in presence of ammonia or amines, or by reduction of nitriles, carboxylic acid amides, imines or imino-ethers by reduction of carboxylic acid amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/02—Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
LTEP05742844.3T 2004-05-05 2005-05-06 Lipidai, lipidų kompleksai ir jų panaudojimas LT1771206T (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04010700 2004-05-05
EP04030847 2004-12-27
PCT/EP2005/004920 WO2005105152A2 (en) 2004-05-05 2005-05-06 Lipids, lipid complexes and use thereof

Publications (1)

Publication Number Publication Date
LT1771206T true LT1771206T (lt) 2018-05-25

Family

ID=34967659

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP05742844.3T LT1771206T (lt) 2004-05-05 2005-05-06 Lipidai, lipidų kompleksai ir jų panaudojimas

Country Status (20)

Country Link
US (7) US8017804B2 (lt)
EP (1) EP1771206B1 (lt)
JP (1) JP5166022B2 (lt)
KR (1) KR101356935B1 (lt)
CN (2) CN1968714B (lt)
AU (1) AU2005237764B2 (lt)
BR (1) BRPI0509471A8 (lt)
CA (1) CA2565633C (lt)
CY (1) CY1120189T1 (lt)
DK (1) DK1771206T3 (lt)
ES (1) ES2668826T3 (lt)
HU (1) HUE036916T2 (lt)
IL (1) IL178879A (lt)
IN (1) IN2014DN02278A (lt)
LT (1) LT1771206T (lt)
MX (1) MXPA06012722A (lt)
PL (1) PL1771206T3 (lt)
PT (1) PT1771206T (lt)
SI (1) SI1771206T1 (lt)
WO (1) WO2005105152A2 (lt)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE350473T2 (de) 2002-08-05 2007-01-15 Atugen Ag Weitere neue formen von interferierende rns moleküle
HUE036916T2 (hu) 2004-05-05 2018-08-28 Silence Therapeutics Gmbh Lipidek, lipid komplexek és ezek alkalmazása
US9393315B2 (en) 2011-06-08 2016-07-19 Nitto Denko Corporation Compounds for targeting drug delivery and enhancing siRNA activity
BRPI0519468A2 (pt) * 2004-12-27 2009-01-27 Silence Therapeutics Ag complexos de lipÍdeos revestido e seu uso
AU2013257401B2 (en) * 2006-04-20 2016-03-17 Silence Therapeutics Gmbh Lipoplex formulations for specific delivery to vascular endothelium
MX2008013416A (es) * 2006-04-20 2008-11-12 Silence Therapeutics Ag Medios para inhibir la expresion de cd31.
WO2007121947A1 (en) * 2006-04-20 2007-11-01 Silence Therapeutics Ag. Lipoplex formulations for specific delivery to vascular endothelium
CN102321626B (zh) * 2006-07-21 2014-12-10 赛伦斯治疗有限公司 用于抑制蛋白激酶3表达的方法
US8193246B2 (en) 2006-12-19 2012-06-05 Marina Biotech, Inc. Lipids and lipid assemblies comprising transfection enhancer elements
WO2008137758A2 (en) 2007-05-04 2008-11-13 Mdrna, Inc. Amino acid lipids and uses thereof
AR067997A1 (es) * 2007-08-24 2009-10-28 Novartis Ag Compuestos organicos
EP2326351B1 (en) 2008-08-19 2017-12-27 Nektar Therapeutics Conjugates of small-interfering nucleic acids
US8722875B2 (en) * 2008-09-23 2014-05-13 Silence Therapeutics Gmbh Means for inhibiting the expression of Orc-1
JP2012517815A (ja) 2009-02-18 2012-08-09 サイレンス・セラピューティクス・アーゲー Ａｎｇ２の発現を阻害するための手段
US8916693B2 (en) 2009-09-17 2014-12-23 Nektar Therapeutics Monoconjugated chitosans as delivery agents for small interfering nucleic acids
US8359883B2 (en) * 2009-11-13 2013-01-29 Hasmukh Dholakiya Gemstone setting
KR101762466B1 (ko) * 2009-12-23 2017-07-27 노파르티스 아게 지질, 지질 조성물 및 이의 사용 방법
JP5510808B2 (ja) * 2010-03-10 2014-06-04 独立行政法人産業技術総合研究所 有機ナノチューブからなる核酸導入剤
WO2011120053A1 (en) 2010-03-26 2011-09-29 Mersana Therapeutics, Inc. Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof
US10196637B2 (en) 2011-06-08 2019-02-05 Nitto Denko Corporation Retinoid-lipid drug carrier
US20150017091A1 (en) 2011-08-18 2015-01-15 Cornell University Detection and treatment of metastatic disease
JP6495408B2 (ja) * 2012-07-06 2019-04-03 協和発酵キリン株式会社 カチオン性脂質
TW201408625A (zh) 2012-07-06 2014-03-01 Kyowa Hakko Kirin Co Ltd 陽離子性脂質
WO2014018375A1 (en) 2012-07-23 2014-01-30 Xenon Pharmaceuticals Inc. Cyp8b1 and uses thereof in therapeutic and diagnostic methods
EP2853595A1 (en) 2013-09-30 2015-04-01 Soluventis GmbH NOTCH 1 specific siRNA molecules
JP2016540769A (ja) * 2013-12-05 2016-12-28 サイレンス・セラピューティクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 肺特異的送達用手段
WO2016083623A1 (en) * 2014-11-28 2016-06-02 Silence Therapeutics Gmbh Means for the treatment of pre-eclampsia
DK3349802T3 (en) * 2015-09-14 2021-10-11 Univ Texas Lipocationic dendrimers and uses thereof
KR101949453B1 (ko) * 2015-12-30 2019-02-18 주식회사 삼양바이오팜 양이온성 지질의 선택적 합성 방법
EP3448393A1 (en) 2016-04-25 2019-03-06 Invivogen Novel complexes of immunostimulatory compounds, and uses thereof
US11352647B2 (en) 2016-08-17 2022-06-07 The Broad Institute, Inc. Crispr enzymes and systems
WO2018035387A1 (en) 2016-08-17 2018-02-22 The Broad Institute, Inc. Novel crispr enzymes and systems
US11458107B2 (en) * 2016-08-25 2022-10-04 The Regents Of The University Of California Abiotic anti-VEGF nanoparticle
EP4035659A1 (en) 2016-11-29 2022-08-03 PureTech LYT, Inc. Exosomes for delivery of therapeutic agents
CA3045131A1 (en) 2016-12-14 2018-06-21 Ligandal, Inc. Methods and compositions for nucleic acid and protein payload delivery
CA3073848A1 (en) 2017-09-21 2019-03-28 The Broad Institute, Inc. Systems, methods, and compositions for targeted nucleic acid editing
EP3710039A4 (en) 2017-11-13 2021-08-04 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR CANCER TREATMENT BY TARGETING THE CLEC2D-KLRB1 PATH
TW201936201A (zh) 2017-12-14 2019-09-16 美商堅固生物科技公司 基因之非病毒生產及遞送
US10968257B2 (en) 2018-04-03 2021-04-06 The Broad Institute, Inc. Target recognition motifs and uses thereof
KR20210056329A (ko) 2018-08-07 2021-05-18 더 브로드 인스티튜트, 인코퍼레이티드 신규 cas12b 효소 및 시스템
US20210292766A1 (en) 2018-08-29 2021-09-23 University Of Massachusetts Inhibition of Protein Kinases to Treat Friedreich Ataxia
JP2021535226A (ja) 2018-09-04 2021-12-16 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム 核酸を臓器特異的送達するための組成物および方法
CA3111484A1 (en) 2018-09-04 2020-03-12 The Board Of Regents Of The University Of Texas System Compositions and methods for organ specific delivery of nucleic acids
WO2020191102A1 (en) 2019-03-18 2020-09-24 The Broad Institute, Inc. Type vii crispr proteins and systems
WO2020236972A2 (en) 2019-05-20 2020-11-26 The Broad Institute, Inc. Non-class i multi-component nucleic acid targeting systems
EP3865122A1 (en) 2020-02-11 2021-08-18 Pantherna Therapeutics GmbH Lipid composition and use thereof for delivery of a therapeutically active agent to endothelium
WO2022097634A1 (ja) * 2020-11-04 2022-05-12 国立大学法人北海道大学 血管新生依存性疾患治療に使用される医薬用組成物
CN113116819B (zh) * 2021-04-24 2022-09-20 郑州大学 一种载siRNA纳米脂质杂化胶束及其制备方法和应用
CN114469863B (zh) * 2021-11-26 2023-09-26 南方医科大学南方医院 甾醇脂质体作为牙髓和牙本质药物传递系统的应用
WO2023196818A1 (en) 2022-04-04 2023-10-12 The Regents Of The University Of California Genetic complementation compositions and methods

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2698628B1 (fr) * 1992-12-02 1995-02-17 Fournier Ind & Sante Analogues de 15-déoxyspergualine, leur procédé de préparation et leur utilisation en thérapeutique.
US5777153A (en) 1994-07-08 1998-07-07 Gilead Sciences, Inc. Cationic lipids
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5820873A (en) 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
IL122290A0 (en) 1995-06-07 1998-04-05 Inex Pharmaceuticals Corp Lipid-nucleic acid complex its preparation and use
US7422902B1 (en) 1995-06-07 2008-09-09 The University Of British Columbia Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US6020526A (en) * 1995-07-21 2000-02-01 Genta, Incorporated Amide-based cationic lipids
CA2217550A1 (en) 1996-10-22 1998-04-22 F. Hoffmann-La Roche Ag Cationic lipids for gene therapy
US6358523B1 (en) 1996-12-06 2002-03-19 The Regents Of The University Of California Macromolecule-lipid complexes and methods for making and regulating
WO1998044909A1 (en) 1997-04-04 1998-10-15 Valentis Inc. Improved methods of delivery using cationic lipids and helper lipids
WO1998051285A2 (en) 1997-05-15 1998-11-19 Genzyme Corporation Cationic amphiphile formulations
US6395713B1 (en) 1997-07-23 2002-05-28 Ribozyme Pharmaceuticals, Inc. Compositions for the delivery of negatively charged molecules
US20030073640A1 (en) 1997-07-23 2003-04-17 Ribozyme Pharmaceuticals, Inc. Novel compositions for the delivery of negatively charged molecules
WO1999004819A1 (en) 1997-07-24 1999-02-04 Inex Pharmaceuticals Corporation Liposomal compositions for the delivery of nucleic acid catalysts
FR2788275B1 (fr) 1999-01-11 2002-06-14 Lipha ((aminoiminomethyl)amino) alcane carboxamides et leurs applications en therapeutique
US7015040B2 (en) 1999-02-26 2006-03-21 Mirus Bio Corporation Intravascular delivery of nucleic acid
CN1228041C (zh) 1999-07-15 2005-11-23 英耐克斯药品股份有限公司 脂质包埋的治疗剂的制备方法
WO2001026625A2 (en) * 1999-10-08 2001-04-19 Alza Corp Neutral-cationic lipid for nucleic acid and drug delivery
MXPA02009485A (es) 2000-03-31 2003-03-10 Kirin Brewery Preparacion en polvo para administracion a traves de la mucosa, que comprende un farmaco de alto peso molecular y que muestra una estabilidad mejorada en almacenamiento.
JP2004508012A (ja) 2000-04-20 2004-03-18 ザ　ユニバーシティ　オブ　ブリティッシュ　コロンビア エンドソーム膜不安定剤を用いたｓｐｌｐ媒介性トランスフェクションの強化方法
EP1328254B1 (en) 2000-10-25 2007-02-21 The University Of British Columbia Lipid formulations for target delivery
US6394713B1 (en) * 2001-03-05 2002-05-28 Phillip E. Yates, Sr. Drill guide apparatus
US20040156816A1 (en) 2002-08-06 2004-08-12 David Anderson Lipid-drug complexes in reversed liquid and liquid crystalline phases
EP1663171B9 (en) 2003-08-26 2009-08-19 SmithKline Beecham Corporation Heterofunctional copolymers of glycerol and polyethylene glycol, their conjugates and compositions
HUE036916T2 (hu) * 2004-05-05 2018-08-28 Silence Therapeutics Gmbh Lipidek, lipid komplexek és ezek alkalmazása
EP1811960A2 (en) 2004-11-19 2007-08-01 Novosom AG Improvements in or relating to pharmaceutical compositions for local administration
BRPI0519468A2 (pt) 2004-12-27 2009-01-27 Silence Therapeutics Ag complexos de lipÍdeos revestido e seu uso
WO2006074546A1 (en) 2005-01-13 2006-07-20 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering rna
WO2007121947A1 (en) 2006-04-20 2007-11-01 Silence Therapeutics Ag. Lipoplex formulations for specific delivery to vascular endothelium

Also Published As

Publication number Publication date
MXPA06012722A (es) 2007-02-14
DK1771206T3 (en) 2018-05-22
PL1771206T3 (pl) 2018-07-31
CN1968714B (zh) 2013-10-16
IL178879A0 (en) 2007-03-08
US9486538B2 (en) 2016-11-08
IL178879A (en) 2013-08-29
US20140329885A1 (en) 2014-11-06
CA2565633C (en) 2016-04-26
US20170036990A1 (en) 2017-02-09
CN1968714A (zh) 2007-05-23
PT1771206T (pt) 2018-05-16
US20150359906A1 (en) 2015-12-17
WO2005105152A3 (en) 2006-09-14
KR20070038954A (ko) 2007-04-11
US20110294871A1 (en) 2011-12-01
EP1771206A2 (en) 2007-04-11
US8735453B2 (en) 2014-05-27
IN2014DN02278A (lt) 2015-07-10
US20120065138A1 (en) 2012-03-15
US20080274116A1 (en) 2008-11-06
CN102940891B (zh) 2016-02-24
US9125820B2 (en) 2015-09-08
AU2005237764A1 (en) 2005-11-10
US8017804B2 (en) 2011-09-13
SI1771206T1 (en) 2018-06-29
US8357722B2 (en) 2013-01-22
BRPI0509471A (pt) 2007-09-11
WO2005105152A2 (en) 2005-11-10
BRPI0509471A8 (pt) 2017-07-25
CA2565633A1 (en) 2005-11-10
CY1120189T1 (el) 2018-12-12
CN102940891A (zh) 2013-02-27
US20130165381A1 (en) 2013-06-27
HUE036916T2 (hu) 2018-08-28
JP5166022B2 (ja) 2013-03-21
JP2007536324A (ja) 2007-12-13
ES2668826T3 (es) 2018-05-22
KR101356935B1 (ko) 2014-01-28
EP1771206B1 (en) 2018-04-11
AU2005237764B2 (en) 2011-11-24

Similar Documents

Publication Publication Date Title
IL178879A0 (en) Lipids, lipid complexes and use thereof
HK1222541A1 (zh) 塗層脂質複合體和它們的用途
IL243998A0 (en) Polar lipid mixtures, their preparation and uses
EP1664316A4 (en) Polyethylphenol-modified lipid compounds and uses thereof
EP2452567B8 (en) Powder being rich in milk-origin complex lipids
GB0704141D0 (en) Topical medicament
EP1723158A4 (en) O, O'-AMIDOMALONATE AND N, O-AMIDOMALONATE PLATINUM COMPLEXES
EP1709889A4 (en) CHAIR
GB0405200D0 (en) Combinations comprising alpha-2-delta ligands
IL177223A (en) Tat complexes, vaccines containing them and their uses
AU302836S (en) Chair
EP1953227A4 (en) BINDER OF LIPOPOLYSACCHARIDE OR LIPID A, AND NEW PEPTIDE
GB0426903D0 (en) Complexes and methods
GB0402491D0 (en) Medicaments
EP1816136A4 (en) GPR7 SELECTIVE LIGAND AND APPLICATION THEREOF
GB0501799D0 (en) Showcase
GB2411582B (en) Tidy
IL163968A0 (en) Phosphatidylserine and lipids formulations
GB0409654D0 (en) Its all in the name
GB0421117D0 (en) Immune complexes
AU3079P (en) Sunbelrikupi Calibrachoa hybrid
GB0515322D0 (en) Ligands and use thereof
AU157125S (en) An armchair
GB0301408D0 (en) It`s all in the name
GB0425283D0 (en) The tote sweepstake